Pancreatic cancer natural history, complications and prognosis

Jump to navigation Jump to search

Pancreatic cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancreatic Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancreatic cancer natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancreatic cancer natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancreatic cancer natural history, complications and prognosis

CDC on Pancreatic cancer natural history, complications and prognosis

Pancreatic cancer natural history, complications and prognosis in the news

Blogs on Pancreatic cancer natural history, complications and prognosis

Directions to Hospitals Treating Pancreatic cancer

Risk calculators and risk factors for Pancreatic cancer natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2] Sudarshana Datta, MD [3]

Overview

The symptoms of pancreatic cancer usually develop in the sixth decade of life, and start with symptoms such as jaundice, light-colored stools, dark urine, pain in the upper or middle abdomen and back, unexplained weight loss, anorexia and fatigue.Symptoms typically develop about 20-30 years after exposure to risk factors such as smoking and alcohol. Genetic factors such as alterations in tumor suppressor genes, oncogenes and different signaling pathways are responsible. If left untreated, patients with pancreatic cancer may progress to develop exocrine pancreatic insufficiency arising from pancreatic duct obstruction leading to malabsorption, malnutrition and cachexia. Dudodenal obstruction and biliary obstruction may cause symptoms of bowel obstruction and jaundice. Common complications of pancreatic cancer may arise as a result of the disease or therapy (surgical or medical). Depending on the extent of the tumor at the time of diagnosis, the prognosis is generally regarded as poor, with complete remission extremely rare.

Natural History, Complications and Prognosis

Natural History

Complications

Malabsorption:

Pain

Jaundice

Duodenal obstruction

Prognosis

  • The primary factors that influence prognosis are:
  • Whether the tumor is localized and can be completely resected
  • Whether the tumor has spread to lymph nodes or elsewhere


  • Staging and TNM (tumour, lymph node, metastasis) classification related to incidence, treatment, and prognosis: [1]
Staging and TNM Classification related to Incidence, Treatment, and Prognosis
Stage TNM Classification Clinical Classification Incidence at diagnosis (%) 5-year survival rate (%)
0 Tis, N0, M0 Resectable 7.5 15.2
IA T1, N0, M0
IB T2, N0, M0
IIA T3, N0, M0
IIB T1-3, N1, M0 Locally advanced 29.3 6.3
III T4, any N, M0
IV Any T, any N, M1 Metastatic 47.2 1.6

The percentage of people who live for a minimum of five years after diagnosis is called the 5- year survival rate. Survival rates for exocrine pancreatic cancer Lifespan is found to be longer in patients treated with surgery, as opposed to other patients. The 5-year survival rate for people at various stages of pancreatic cancer are as follows:

stage IA: 14% 

stage IB cancer 12% stage IIA 7%

stage IIB 5%

stage III 3% Stage IV 1% • Survival rates for neuroendocrine pancreatic tumors (treated with surgery) • stage I pancreatic NETs 61%. • stage II pancreatic NETs 52%. • stage III pancreatic NETs 41%. • Stage IV pancreatic NETs 16%. Still, • tumors not removed by surgery was 16%

References

  1. Bond-Smith G, Banga N, Hammond TM, Imber CJ (2012). "Pancreatic adenocarcinoma". BMJ. 344: e2476. doi:10.1136/bmj.e2476. PMID 22592847.



Template:WikiDoc Sources